<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3301">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04259892</url>
  </required_header>
  <id_info>
    <org_study_id>C20-06</org_study_id>
    <secondary_id>2020-A00280-39</secondary_id>
    <nct_id>NCT04259892</nct_id>
  </id_info>
  <brief_title>Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection. COVID-19.</brief_title>
  <acronym>Cov-CONTACT</acronym>
  <official_title>Viral Excretion in Contact Subjects at High/Moderate Risk of Coronavirus 2019-nCoV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of
      Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has
      dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on
      March, 16th 2020.

      Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2
      in the community and within the hospital.

      Depending on the country, contact subjects considered to be at high or moderate risk of
      SARS-CoV-2 are, either isolated at home for a period of time defined by the health
      authorities or, on the contrary, continue their professional activity on the condition that
      they adopt measures to prevent transmission to those around them. In most European countries,
      healthcare workers adopt this second option. In all cases, it is most often recommended that
      contact persons monitor their state of health and communicate it to the persons dedicated to
      this action.

      Whether such subjects become spreaders of the virus is not known, nor is the proportion of
      viral spreader who will develop a symptomatic infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedures added by the research:

      Phone calls for collection of reported symptoms. Nasopharyngeal swabs for determination of
      the presence of SARS-CoV-2 detected by PCR.

      Blood sampling for determination of the presence of SARS-CoV-2 IgM or IgG. Saliva or blood
      sampling for whole exome sequencing of the subject.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2020</start_date>
  <completion_date type="Anticipated">February 4, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 4, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to SARS-CoV-2 nasopharyngeal excretion, from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.</measure>
    <time_frame>12 days (+/-2)</time_frame>
    <description>PCR at day 0, day 3, day 5, day 7 and day 12 following the last high/moderate risk contact</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to apparition of any symptom suggestive of SARS-CoV-2 from the day of the first high/moderate risk contact to 12 days after the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.</measure>
    <time_frame>12 days (+/-2)</time_frame>
    <description>Patient Reported Outcome assessed daily (fever &gt; 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with the time to SARS-CoV-2 nasopharyngeal excretion</measure>
    <time_frame>12 days (+/-2)</time_frame>
    <description>nasopharyngeal excretion assessed by PCR at day 0, day 3, day 5, day 7 and day 12 following the last high/moderate risk contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors associated with the time to apparition of any symptom suggestive of SARS-CoV-2 infection</measure>
    <time_frame>12 days (+/-2)</time_frame>
    <description>Patient Reported Outcome assessed daily (fever &gt; 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of contact subjects with apparition of any symptom suggestive of SARS-CoV-2 infection</measure>
    <time_frame>12 days (+/-2)</time_frame>
    <description>Patient Reported Outcome assessed daily (fever &gt; 38°C, asthenia/fatigue/malaise, headache, thrills/sweating, myalgia/aches, cough, dyspnea, Acute Respiratory Distress Syndrome, diarrhea, abdominal pain, ...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of contact subjects with positive serology defined as the presence of SARS-CoV-2 IgM or IgG at day 30 (+/-7) following last contact</measure>
    <time_frame>30 days (+/-7)</time_frame>
    <description>ELISA, microneutralisation essay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Host genetic variants</measure>
    <time_frame>1 day</time_frame>
    <description>Whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.</measure>
    <time_frame>365 days (+/-30)</time_frame>
    <description>ELISA, microneutralisation essay</description>
  </secondary_outcome>
  <enrollment type="Anticipated">345</enrollment>
  <condition>Coronavirus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2019-nCoV PCR</intervention_name>
    <description>Nasopharyngeal swabs</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasopharyngeal swabs
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is represented by all subjects who had a contact with
        laboratory-confirmed SARS-CoV-2 cases and whose contact was considered to be at
        high/moderate risk of SARS-CoV-2 acquisition.

        This include both children and adult subjects, and healthcare workers. It may also include
        subject without social security in some countries, according to local legislation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. High/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case;

          2. Within the 14 days following the last contact with a laboratory-confirmed SARS-CoV-2
             case;

          3. Obtaining informed consent.

        Exclusion Criteria:

          -  Subject deprived of freedom

          -  Subject under a legal protective measure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Duval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Duval, MD</last_name>
    <phone>01 40 25 71 48</phone>
    <email>xavier.duval@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno Lina, MD</last_name>
    <email>bruno.lina@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine CHIROUZE, MD</last_name>
      <phone>+ 33 3 81 21 85 33</phone>
      <email>catherine.chirouze@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry PISTONE, MD</last_name>
      <phone>+33 5 56 79 21 73</phone>
      <email>thierry.pistone@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri LAURICHESSE, MD</last_name>
      <phone>+33 4 73 93 71 49</phone>
      <email>hlaurichesse@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21 079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc BARDOU, MD</last_name>
      <phone>+33 380 393 433</phone>
      <email>marc.bardou@u-bourgogne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique 1406 CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean luc CRACOWSKI, MD</last_name>
      <phone>+33 4 76 76 92 60</phone>
      <email>JLCracowski@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique 1403 -CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DEPLANQUE, MD</last_name>
      <phone>+33 3 20 44 68 91</phone>
      <email>dominique.deplanque@univ-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Investigation Clinique 1433 CHRU de NANCY</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis GUILLEMIN, MD</last_name>
      <phone>+33 3 83 85 21 65</phone>
      <email>francis.guillemin@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques KILADJIAN, MD</last_name>
      <phone>+33 1 42 49 94 94</phone>
      <email>jean-jacques.kiladjian@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DUVAL, MD</last_name>
      <phone>+33 1 40 25 71 48</phone>
      <email>xavier.duval@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Investigation Clinique 1417 Hôpital Cochin Bâtiment Lavoisier</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile LAUNAY, MD</last_name>
      <phone>+33 1 58 41 28 58</phone>
      <email>Odile.launay@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LAVIOLLE, MD</last_name>
      <phone>+33 2 99 28 96 68</phone>
      <email>bruno.laviolle@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord</name>
      <address>
        <city>Saint Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léa BRUNEAU, MD</last_name>
      <phone>+262 2 62 90 68 83</phone>
      <email>lea.bruneau@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Ile de la Réunion CHU sud</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick GERARDIN, MD</last_name>
      <phone>+262 2.62.35.90.00</phone>
      <phone_ext>+ 5.42.71</phone_ext>
      <email>patrick.gerardin@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département maladie infectieux CHU Saint Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth BOTELHO-NEVERS, MD</last_name>
      <phone>+33 4 77 82 92 34</phone>
      <email>elisabeth.botelho-nevers@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie GISSOT, MD</last_name>
      <phone>+33 2 34 37 96 53</phone>
      <email>valerie.gissot@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses et tropicales Centre hospitalier</name>
      <address>
        <city>Cayenne</city>
        <zip>97306</zip>
        <country>French Guiana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Félix DJOSSOU, MD</last_name>
      <phone>+594 5 94 39 50 40</phone>
      <email>felix.djossou@ch-cayenne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>French Guiana</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact subject</keyword>
  <keyword>high/moderate risk of transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

